Code
MOG-BTKX-03BZ
Panel
Active-Compendium
81479
Clinical
Oncology,Pathology
Flag Active
True
Orderable Test Description
<p>This product has been discontinued. Please see below for alternative testing options.<br><br><strong>Comprehensive:</strong><br>* <a href="https://www.neogenomics.com/providers/test/NTG-HCSX-02BX/neo-comprehensive-heme-cancers" rel="nofollow">Neo Comprehensive - Heme Cancers</a><br><br><strong>Targeted:</strong><br>* <a href="https://www.neogenomics.com/providers/test/NTG-LDPX-02CX/neotype-lymphoid-disorders-profile" rel="nofollow">NeoTYPE Lymphoid Disorders Profile</a><br><br><strong>Additional Alternative Options:</strong><br>* <a href="https://www.neogenomics.com/providers/test/NTG-CLPX-02CX/neotype-cll-profile" rel="nofollow">NeoTYPE CLL Profile</a><br><br>
If you have any questions regarding test discontinuations, please contact your local NeoGenomics Sales Representative or our Client Services team at Client.Services@NeoGenomics.com or call 866.776.5907, option 3.</p>
If you have any questions regarding test discontinuations, please contact your local NeoGenomics Sales Representative or our Client Services team at Client.Services@NeoGenomics.com or call 866.776.5907, option 3.</p>
Keywords
NY Approved
False
Keywords string
BTK, BTK Inhibitor, BTK Inhibitor Resistance, ibrutinib, CLL, bruton tyrosine kinase, PLC-gamma-2, acquired resistance BTK Inhibitor Acquired Resistance Panel
Title URL
btk-inhibitor-acquired-resistance-panel